Abstract Number: 403 • 2019 ACR/ARP Annual Meeting
Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome
Background/Purpose: Autoantibodies (aAbs) to proteins comprising the survival of motor neuron (SMN) macromolecular complex have not been thoroughly studied. Only two publications described clinical associations…Abstract Number: 407 • 2019 ACR/ARP Annual Meeting
Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases affecting multiple organ systems and associated with a diverse autoantibody profile. Anti-SSA/SSB are the most frequent…Abstract Number: 1275 • 2019 ACR/ARP Annual Meeting
Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases with systemic features and multiple comorbidities. Of the myositis associated antibodies seen in this population, anti-SSA/SSB…Abstract Number: 1276 • 2019 ACR/ARP Annual Meeting
Myositis Specific Antibodies and Clinical Features in Patients from Argentina
Background/Purpose: To know the frequency of myositis specific antibodies (MSAs) and myositis associated antibodies( MAAs) and their relation with clinical features in patients with idiopathic…Abstract Number: 1277 • 2019 ACR/ARP Annual Meeting
Damage and Comorbidities in a Cohort of Patients with Idiopathic Inflammatory Myopathy
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) remain a major clinical challenge worldwide. The precise aetiopathogenesis of this chronic and disabling disorder remains elusive which precludes the…Abstract Number: 1280 • 2019 ACR/ARP Annual Meeting
JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Background/Purpose: We previously observed in vitro that IFN-I reproduces dermatomyositis (DM) pathological findings, that pathogenic effects may be prevented in vitro by JAK inhibitor (JAKinh) therapy and an improvement…Abstract Number: 1283 • 2019 ACR/ARP Annual Meeting
Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study
Background/Purpose: The association between idiopathic inflammatory myopathies (IIMs) and malignancies in Thai population has been rarely reported. The objective of our study was to determine…Abstract Number: 1284 • 2019 ACR/ARP Annual Meeting
Idiopathic Inflammatory Myopathies: Are Muscle Biopsies Still Needed?
Background/Purpose: Inflammatory myopathies (IM) are a heterogeneous group of diseases characterized by muscle inflammation. In Argentina, there are few pathologists specialized in muscle biopsies and…Abstract Number: 1871 • 2019 ACR/ARP Annual Meeting
Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury
Background/Purpose: Myositis-specific antibodies (MSAs) are identified in over half of children with JDM and are associated with distinct clinical phenotypes. MSA subtype, in combination with…Abstract Number: 2272 • 2019 ACR/ARP Annual Meeting
Self-reported Anxiety, Depression and Levels of Physical Activity in Patients with Adult Idiopathic Inflammatory Myopathies
Background/Purpose: The adult idiopathic inflammatory myopathies (IIM) comprise dermatomyositis (DM), necrotizing myopathy (NM), antisynthetase syndrome (ASS), overlap myositis and inclusion body myositis (IBM). Impaired muscle…Abstract Number: 2842 • 2019 ACR/ARP Annual Meeting
Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control
Background/Purpose: Inflammation and damage to the vascular endothelium are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis. Paraoxonase 1 (PON1) is a…Abstract Number: 389 • 2019 ACR/ARP Annual Meeting
ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis
Background/Purpose: Autoimmune myositis consists of a group of diseases with heterogeneous muscular and systemic manifestations. Prognosis also varies widely across the spectrum. Thus, myositis subgroups…Abstract Number: 398 • 2019 ACR/ARP Annual Meeting
Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong
Background/Purpose: Seasonal patterns of disease onset and severity in idiopathic inflammatory myopathies (IIMs) as a whole are conflicting. In recent years, over 10 myositis-specific antibodies…Abstract Number: 400 • 2019 ACR/ARP Annual Meeting
Performance of the European League Against Rheumatism/American College of Rheumatology Idiopathic Inflammatory Myopathies Classification Criteria in a Myositis Cohort from Argentina
Background/Purpose: Patients with Idiopathic Inflammatory Myopathies (IIM) have been classified mainly according to Bohan and Peter (B&P) criteria, proposed in 1975. In 2017 the new…Abstract Number: 336 • 2018 ACR/ARHP Annual Meeting
Physical Activity Monitors: New Tool to Assess Improvement in Myositis
Background/Purpose: Physical activity monitors (PAM) are increasing being used to objectively quantify free-living movement in clinical research, especially musculoskeletal diseases. Given that patients with idiopathic…
- 1
- 2
- 3
- 4
- Next Page »